chemotherapy

Germany’s Merck Ends Bavencio Pact with Pfizer

Germany’s Merck will regain exclusive worldwide rights to develop, manufacture and commercialize the anti-programmed death ligand-1 (PD-L1) antibody Bavencio (avelumab) following the termination of its Alliance agreement with US drugs giant Pfizer, planned for the end of the second quarter.

News

Manufacturing of HPAPIs and ADC Toxins for the Drugs of Tomorrow

Top-Feature

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Citrine

Operationalizing AI in Polymer Development: How Syensqo Is Scaling Impact with the Citrine Platform

Aenova Holding GmbH

Mastering Modified Release: The Pellet-Based Approach

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

Global Impact Coalition (GIC)

Siemens Joins the Global Impact Coalition

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

Article

Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Groupe Novasep